Treatment for patients with acute ischemic stroke presenting beyond six hours of ischemic symptom onset: Effectiveness of intravenous direct thrombin inhibitor, argatroban

Journal of Korean Neurosurgical Society

Volumn 47, Issue 4, 2010, Pages 258-264

  Park, Jung Soo ^a   Park, Seung Soo ^a   Koh, Eun Jeong ^a   Eun, Jong Pil ^a   Choi, Ha Young ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Acute ischemic stroke; Intravenous argatroban

Indexed keywords

ARGATROBAN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 77952935293     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2010.47.4.258     Document Type: Article

References (26)

1. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, et al.: Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 53: 126-131, 1999
2. Biller J, Love BB, Marsh EE 3rd, Jones MP, Knepper LE, Jiang D, et al.: Spontaneous improvement after acute ischemic stroke. A pilot study. Stroke 21: 1008-1012, 1990
3. Escolar G, Bozzo J, Maragall S: Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today (Bare) 42: 223-236, 2006
4. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al.: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282: 2003-2011, 1999
5. Gubitz G, Counsell C, Sandercock P, Signorini D: Anticoagulants for acute ischemic stroke. Cochrane Database Syst Rev: 2000;(2):CD000024
6. Hosomi N, Naya T, Kohno M, Kobayashi S, Koziol JA; Japan Standard Stroke Registry Study Group: Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke. J Neurol 254: 605-612, 2007
7. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS: Factors delaying hospital admission in acute stroke: the Copenhagen Stroke Study. Neurology 47: 383-387, 1996
8. Jovin TG, Gupta R, Uchino K, Jungreis CA, Wechsler LR, Hammer MD, et al.: Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate. Stroke 36:2426-2430, 2005
9. Kawai H, Yuki S, Sugimoto J, Tamao Y: Effects of a thrombin inhi- bitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 278: 780- 785, 1996
10. Keris V, Rudnicka S, Vorona V, Enina G, Tilgale B, Fricbergs J: Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 22: 352-358, 2001
11. Kobayashi S, Kitani M, Yamaguchi S, Suzuki T, Okada K, Tsune-matsu T: Effects of an antithrombotic agent (MD-805) on progressing cerebral thrombosis. Thromb Res 53: 305-317, 1989
12. Kobayashi S, Tazaki Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 23: 531-534, 1997
13. LaMonte MP: Argatroban in thrombotic stroke. Pathophysiol Hae-most Thromb 32 Suppl 3: 39-45, 2002
14. LaMonte MP, Brown PM, Hursting MJ: Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor. Expert Rev Cardiovasc Ther 3: 31 -41, 2005
15. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, et al.: Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 35: 1677-1682, 2004
16. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, et al.: Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 32: 2635-2640, 2001
17. Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, Cacayorin ED, et al.: Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke 36: 292296, 2005
18. Ok YC, Park SK, Cho KY, Lim JS, Lee RS: Epidemiology and characteristics of recurrent stroke: The occurrence type of restroke is similar as previous stroke. J Korean Neurosurg Soc 41: 224-229, 2007
19. Park HS, Kang MJ, Huh JT: Recent epidemiological trends of stroke. J Korean Neurosurg Soc 43: 16- 20, 2008
20. Sandercock PA, Counsell C, Kamal AK: Anticoagulants for acute ischemic stroke. Cochrane Database Syst Rev: 2008 oct 8;CD000024
21. Saposnik G, Di Legge S, Webster F, Hachinski V: Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology 65: 1169-1174, 2005
22. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rTPA Stroke Study Group: N Engl J Med 333: 1581-1587, 1995
23. Toni D, Lorenzano S, Sacchetti ML, Fiorelli M, De Michele M, Principe M: Specific therapies for ischaemic stroke: rTPA and others. Neurol Sci 26 Suppl 1: S26-S28, 2005
24. Urabe T, Tanaka R, Noda K, Mizuno Y: Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy. J Thromb Thrombolysis 13: 155-160, 2002
25. Wityk RJ, Pessin MS, Kaplan RF, Caplan LR: Serial assessment of acute stroke using the NIH Stroke Scale. Stroke 25: 362-365, 1994
26. Yoneda Y, Mori E, Uehara T, Yamada O, Tabuchi M: Referral and care for acute ischemic stroke in a Japanese tertiary emergency hospital. Eur J Neurol 8: 483-488, 2001